Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
PLoS One ; 12(12): e0189739, 2017.
Article in English | MEDLINE | ID: mdl-29267373

ABSTRACT

The main objective of the study was to find genetic variants that in combination are significantly associated with bipolar disorder. In previous studies of bipolar disorder, combinations of three and four single nucleotide polymorphisms (SNP) genotypes taken from 803 SNPs were analyzed, and five clusters of combinations were found to be significantly associated with bipolar disorder. In the present study, combinations of ten SNP genotypes taken from the same 803 SNPs were analyzed, and one cluster of combinations was found to be significantly associated with bipolar disorder. Combinations from the new cluster and from the five previous clusters were identified in the genomes of 266 or 44% of the 607 patients in the study whereas none of the 1355 control participants had any of these combinations in their genome.The SNP genotypes in the smaller combinations were the normal homozygote, heterozygote or variant homozygote. In the combinations containing 10 SNP genotypes almost all the genotypes were the normal homozygote. Such a finding may indicate that accumulation in the genome of combinations containing few SNP genotypes may be a risk factor for bipolar disorder when those combinations contain relatively many rare SNP genotypes, whereas combinations need to contain many SNP genotypes to be a risk factor when most of the SNP genotypes are the normal homozygote.


Subject(s)
Bipolar Disorder/genetics , Polymorphism, Single Nucleotide , Case-Control Studies , Cluster Analysis , Genetic Predisposition to Disease , Genotype , Humans
2.
Psychiatry Res ; 256: 176-179, 2017 10.
Article in English | MEDLINE | ID: mdl-28645077

ABSTRACT

The brain-derive neurotrophic factor (BDNF) may play an important role in the course of depression. We aimed to study the associations between peripheral whole blood BDNF levels in healthy individuals with and without a family history of depression. BDNF levels were significantly increased in healthy individuals with (n = 76), compared with healthy individuals without (n = 39) a family history of depression and persisted after adjustment for age and gender differences. Higher BDNF levels were associated with increasing age and seasonality. A family history of depression may contribute to an elevation of peripheral BDNF levels in healthy individuals.


Subject(s)
Brain-Derived Neurotrophic Factor/blood , Depression/blood , Depressive Disorder/blood , Adolescent , Adult , Depression/genetics , Depressive Disorder/genetics , Family , Female , Humans , Male , Middle Aged , Sex Factors , Young Adult
3.
Nord J Psychiatry ; 70(4): 297-302, 2016.
Article in English | MEDLINE | ID: mdl-26752119

ABSTRACT

Background Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed as first-line drugs for the treatment of depression. However, the mechanisms of action for SSRIs are unclear and besides neurotransmitter modulation may depend on modulation of the hypothalamic-pituitary-adrenal (HPA) system. The glucocorticoid receptor (GR) isoform α plays an important role in the negative feedback regulation of the HPA axis and reduced GRα messenger RNA (mRNA) expression has been shown in mood disorder patients and first-degree relatives compared to healthy individuals with no family history of psychiatric disorders. Aim Based on the AGENDA trial dataset, we analysed whether an intervention with SSRI versus placebo decreases the GRα mRNA expression in peripheral blood cells in healthy first-degree relatives of patients with major depression. Methods The participants (N = 80) were randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks. GRα mRNA expression levels in peripheral blood were measured using reverse transcription polymerase chain reaction. Results Four weeks of intervention with escitalopram decreased the relative change from baseline in the expression of GRα mRNA compared with placebo (p = 0.002). Conclusion These findings from a randomized trial suggest that a 4-week escitalopram administration to healthy participants results in a decrease in GRα mRNA expression levels in peripheral blood compared with inert placebo. The decrease in GRα mRNA expression levels may reflect a decrease in the HPA axis activity.


Subject(s)
Citalopram/pharmacology , Depression/metabolism , Depressive Disorder, Major/metabolism , RNA, Messenger/drug effects , Receptors, Glucocorticoid/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Adult , Citalopram/therapeutic use , Depression/drug therapy , Depression/genetics , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/genetics , Double-Blind Method , Female , Humans , Hypothalamo-Hypophyseal System/metabolism , Male , Pituitary-Adrenal System/drug effects , Pituitary-Adrenal System/metabolism , Receptors, Glucocorticoid/genetics , Selective Serotonin Reuptake Inhibitors/therapeutic use , Treatment Outcome , Young Adult
4.
Acta Neuropsychiatr ; 28(2): 101-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26573431

ABSTRACT

OBJECTIVE: Brain-derived neurotrophic factor (BDNF) seems to play an important role in the course of depression including the response to antidepressants in patients with depression. We aimed to study the effect of an antidepressant intervention on peripheral BDNF in healthy individuals with a family history of depression. METHODS: We measured changes in BDNF messenger RNA (mRNA) expression and whole-blood BDNF levels in 80 healthy first-degree relatives of patients with depression randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks. RESULTS: We found no statistically significant difference between the escitalopram and the placebo group in the change in BDNF mRNA expression and whole-blood BDNF levels. Post hoc analyses showed a statistically significant negative correlation between plasma escitalopram concentration and change in whole-blood BDNF levels in the escitalopram-treated group. CONCLUSION: The results of this randomised trial suggest that escitalopram 10 mg has no effect on peripheral BDNF levels in healthy individuals.


Subject(s)
Brain-Derived Neurotrophic Factor/biosynthesis , Citalopram/pharmacology , Adult , Antidepressive Agents, Second-Generation/blood , Antidepressive Agents, Second-Generation/pharmacology , Brain-Derived Neurotrophic Factor/blood , Citalopram/blood , Depression/metabolism , Double-Blind Method , Family Health , Female , Healthy Volunteers , Humans , Male , Young Adult
5.
PLoS One ; 10(11): e0143432, 2015.
Article in English | MEDLINE | ID: mdl-26587987

ABSTRACT

The main objective of the study was to find combinations of genetic variants significantly associated with bipolar disorder. In a previous study of bipolar disorder, combinations of three single nucleotide polymorphism (SNP) genotypes taken from 803 SNPs were analyzed, and four clusters of combinations were found to be significantly associated with bipolar disorder. In the present study, combinations of four SNP genotypes taken from the same 803 SNPs were analyzed, and one cluster of combinations was found to be significantly associated with bipolar disorder. Combinations from the new cluster and from the four previous clusters were identified in the genomes of 209 of the 607 patients in the study whereas none of the 1355 control participants had any of these combinations in their genome.


Subject(s)
Bipolar Disorder/genetics , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Case-Control Studies , Cluster Analysis , Denmark , Genotype , Humans , Models, Genetic , Models, Statistical , Norway , Risk Factors
6.
Psychiatr Genet ; 24(1): 37-41, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24362369

ABSTRACT

We analysed single nucleotide polymorphisms in two transmembrane genes (TMEM98 and TMEM132E) in panic disorder (PD) patients and control individuals from the Faroe Islands, Denmark and Germany. The genes encode single-pass membrane proteins and are located within chromosome 17q11.2-q12, a previously reported candidate region for PD. Three single nucleotide polymorphisms (rs887231, rs887230 and rs4795942) located upstream and within TMEM132E showed a nominal significant association with PD primarily in the Danish cohort. No nominal significant associations were observed between TMEM98 and PD. Our data indicate that TMEM132E might contribute moderately towards the risk of developing PD.


Subject(s)
Membrane Proteins/genetics , Panic Disorder/genetics , Case-Control Studies , Chromosomes, Human, Pair 17 , Humans , Polymorphism, Single Nucleotide
8.
PLoS One ; 7(9): e44623, 2012.
Article in English | MEDLINE | ID: mdl-23028568

ABSTRACT

Complex diseases may be associated with combinations of changes in DNA, where the single change has little impact alone. In a previous study of patients with bipolar disorder and controls combinations of SNP genotypes were analyzed, and four large clusters of combinations were found to be significantly associated with bipolar disorder. It has now been found that these clusters may be connected to clinical data.


Subject(s)
Bipolar Disorder/genetics , Female , Genetic Predisposition to Disease/genetics , Genotype , Humans , Male , Polymorphism, Single Nucleotide/genetics
9.
Med Hypotheses ; 78(6): 732-4, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22424717

ABSTRACT

A complex disease with an inheritable component is polygenic, meaning that several different changes in DNA are the genetic basis for the disease. Such a disease may also be genetically heterogeneous, meaning that independent changes in DNA, i.e. various genotypes, can be the genetic basis for the disease. Each of these genotypes may be characterized by specific combinations of key genetic changes. It is suggested that even if all key changes are found in genes related to the biology of a certain disease, the number of combinations may be so large that the number of different genotypes may be close to the number of patients suffering from the disease. This hypothesis is based on a study of bipolar disorder.


Subject(s)
Bipolar Disorder/genetics , Brain/physiopathology , Cell Communication/genetics , Genetic Diseases, Inborn/genetics , Genetic Variation , Multifactorial Inheritance/genetics , Cell Communication/physiology , Genotype , Humans , Polymorphism, Single Nucleotide/genetics
10.
Eur J Hum Genet ; 20(1): 84-90, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21811305

ABSTRACT

Panic disorder (PD) is a mental disorder with recurrent panic attacks that occur spontaneously and are not associated to any particular object or situation. There is no consensus on what causes PD. However, it is recognized that PD is influenced by environmental factors, as well as genetic factors. Despite a significant hereditary component, genetic studies have only been modestly successful in identifying genes of importance for the development of PD. In this study, we conducted a genome-wide scan using microsatellite markers and PD patients and control individuals from the isolated population of the Faroe Islands. Subsequently, we conducted a fine mapping, which revealed the amiloride-sensitive cation channel 1 (ACCN1) located on chromosome 17q11.2-q12 as a potential candidate gene for PD. The further analyses of the ACCN1 gene using single-nucleotide polymorphisms (SNPs) revealed significant association with PD in an extended Faroese case-control sample. However, analyses of a larger independent Danish case-control sample yielded no substantial significant association. This suggests that the possible risk alleles associated in the isolated population are not those involved in the development of PD in a larger outbred population.


Subject(s)
Epithelial Sodium Channels/genetics , Genome-Wide Association Study , Nerve Tissue Proteins/genetics , Panic Disorder/genetics , Acid Sensing Ion Channels , Alleles , Case-Control Studies , Chromosome Mapping , Chromosomes, Human, Pair 17/genetics , Degenerin Sodium Channels , Denmark/epidemiology , Denmark/ethnology , Ethnicity/genetics , Genotype , Humans , Microsatellite Repeats , Panic Disorder/diagnosis , Panic Disorder/epidemiology , Polymorphism, Single Nucleotide , Population Groups/genetics
11.
Acta Neuropsychiatr ; 24(2): 81-90, 2012 Apr.
Article in English | MEDLINE | ID: mdl-26952950

ABSTRACT

OBJECTIVE: There is clear evidence of a genetic component in major depression, and several studies indicate that neuropeptide Y (NPY) could play an important role in the pathophysiology of the disease. A well-known polymorphism encoding the substitution of leucine to proline in the signal peptide sequence of NPY (Leu7Pro variation) was previously found to protect against depression. Our study aimed at replicating this association in a large Danish population with major depression. METHOD: Leu7Pro was studied in a sample of depressed patients and ethnically matched controls, as well as psychiatric disease controls with schizophrenia. Possible functional consequences of Leu7Pro were explored in vitro. RESULTS: In contrast to previous studies, Pro7 appeared to be a risk allele for depression, being significantly more frequent in the depression sample (5.5%, n = 593; p = 0.009; odds ratio, OR: 1.46) as compared to ethnically matched controls (3.8%, n = 2912), while schizophrenia patients (4.1%, n = 503) did not differ. In vitro, the Pro7 substitution appeared to be associated with reduced levels of NPY without affecting its mRNA level. CONCLUSION: The Leu7Pro variation may increase the risk of major depression, possibly by affecting the biosynthesis of NPY.

12.
Am J Med Genet B Neuropsychiatr Genet ; 156B(8): 969-74, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21972176

ABSTRACT

Genetic variants in ankyrin 3 (ANK3) have recently been shown to be associated with bipolar disorder (BD). We genotyped three ANK3 SNPs previously found to be associated with BD (rs10994336, rs1938526, and rs9804190) in a Scandinavian BD case-control sample (N = 854/2,614). Due to evidence of genetic overlap between BD and schizophrenia (SZ), we also genotyped these three SNPs in a Scandinavian SZ case-control sample (N = 1,073/2,919). Combining our Scandinavian samples with an Icelandic sample (N = 435 BD cases, 651 SZ cases, and 11,491 healthy controls), we found rs10994336 and rs9804190 to be nominally significantly associated with BD in this combined Nordic BD sample (N = 1,289/14,105). Nominal P was 0.015/0.018 (fixed/random effect) for rs10994336 (Bonferroni corrected P = 0.044/0.053) and 0.023 for rs9804190 (Bonferroni corrected P = 0.069). None of the SNPs were significantly associated with SZ in the combined Nordic SZ case-control sample (N = 1,724/14,410). These results further support that ANK3 is a susceptibility gene specific to BD and that more than one risk locus is involved.


Subject(s)
Ankyrins/genetics , Bipolar Disorder/genetics , Genetic Association Studies , Schizophrenia/genetics , Case-Control Studies , Female , Gene Frequency , Genetic Predisposition to Disease , Genetic Variation , Genotype , Humans , Iceland , Male , Polymorphism, Single Nucleotide , Scandinavian and Nordic Countries
13.
PLoS One ; 6(8): e23812, 2011.
Article in English | MEDLINE | ID: mdl-21897858

ABSTRACT

Any given single nucleotide polymorphism (SNP) in a genome may have little or no functional impact. A biologically significant effect may possibly emerge only when a number of key SNP-related genotypes occur together in a single organism. Thus, in analysis of many SNPs in association studies of complex diseases, it may be useful to look at combinations of genotypes. Genes related to signal transmission, e.g., ion channel genes, may be of interest in this respect in the context of bipolar disorder. In the present study, we analysed 803 SNPs in 55 genes related to aspects of signal transmission and calculated all combinations of three genotypes from the 3×803 SNP genotypes for 1355 controls and 607 patients with bipolar disorder. Four clusters of patient-specific combinations were identified. Permutation tests indicated that some of these combinations might be related to bipolar disorder. The WTCCC bipolar dataset were use for replication, 469 of the 803 SNP were present in the WTCCC dataset either directly (n = 132) or by imputation (n = 337) covering 51 of our selected genes. We found three clusters of patient-specific 3×SNP combinations in the WTCCC dataset. Different SNPs were involved in the clusters in the two datasets. The present analyses of the combinations of SNP genotypes support a role for both genetic heterogeneity and interactions in the genetic architecture of bipolar disorder.


Subject(s)
Bipolar Disorder/genetics , Bipolar Disorder/pathology , Computational Biology , Polymorphism, Single Nucleotide/genetics , Signal Transduction/genetics , Case-Control Studies , Databases, Factual , Genome-Wide Association Study , Heterozygote , Homozygote , Humans , Reproducibility of Results
14.
J Neurosurg Anesthesiol ; 23(4): 304-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21709586

ABSTRACT

OBJECTIVE: The intron 16 insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene has been associated with rupture of intracranial aneurysms, but the effect of haplotypes within ACE has not been studied. This study investigated whether ACE haplotypes including the I/D polymorphism are associated with aneurysmal subarachnoid hemorrhage. METHODS: The hypothesis was tested with a case-control design in 176 patients with aneurysmal subarachnoid hemorrhage and with 498 hospital controls. Through the pairwise tagging principle, single nucleotide polymorphisms (rs4291 A/T, rs4295 C/G, rs4305 C/T, rs4311 C/T, rs4331 T/C, rs4343 C/T) in the ACE gene were genotyped along with the I/D polymorphism. Haplotypes were estimated using the PHASE software. RESULTS: Fifty-five haplotypes were identified with 3 of these having a frequency above 5%: ACCCCIT (41.6±0.4%), TGTTTDC (32.1±0.5%), and ACCTTDC (9.5±0.2%). No significant difference in distribution of alleles, genotypes, haplotypes, or haplotype pairs between the 2 populations was found. Specifically, we could not reproduce previously reported associations between the ACE I genotype and intracranial aneurysms. When subdivided into groups of aneurysm location, we found a trend toward an association between homozygotes of the ACCCCIT haplotype and middle cerebral artery aneurysms, odds ratio=2.9 (1.0 to 7.6), which however proved insignificant (P=0.22) after correction for multiple testing. CONCLUSION: In this Danish population, ACE haplotypes and the I/D polymorphism did not contribute significantly to the overall risk of intracranial aneurysm rupture. Larger studies are needed to delineate the association between ACE polymorphism and ruptured middle cerebral artery aneurysms.


Subject(s)
Peptidyl-Dipeptidase A/genetics , Subarachnoid Hemorrhage/genetics , Adolescent , Adult , Aged , Alleles , Case-Control Studies , DNA/genetics , DNA/isolation & purification , Denmark/epidemiology , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Haplotypes , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Subarachnoid Hemorrhage/epidemiology , Young Adult
15.
Genet Epidemiol ; 35(5): 318-32, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21484861

ABSTRACT

Meta-analyses of large-scale association studies typically proceed solely within one data type and do not exploit the potential complementarities in other sources of molecular evidence. Here, we present an approach to combine heterogeneous data from genome-wide association (GWA) studies, protein-protein interaction screens, disease similarity, linkage studies, and gene expression experiments into a multi-layered evidence network which is used to prioritize the entire protein-coding part of the genome identifying a shortlist of candidate genes. We report specifically results on bipolar disorder, a genetically complex disease where GWA studies have only been moderately successful. We validate one such candidate experimentally, YWHAH, by genotyping five variations in 640 patients and 1,377 controls. We found a significant allelic association for the rs1049583 polymorphism in YWHAH (adjusted P = 5.6e-3) with an odds ratio of 1.28 [1.12-1.48], which replicates a previous case-control study. In addition, we demonstrate our approach's general applicability by use of type 2 diabetes data sets. The method presented augments moderately powered GWA data, and represents a validated, flexible, and publicly available framework for identifying risk genes in highly polygenic diseases. The method is made available as a web service at www.cbs.dtu.dk/services/metaranker.


Subject(s)
Genome-Wide Association Study/statistics & numerical data , Bipolar Disorder/genetics , Data Interpretation, Statistical , Databases, Genetic , Diabetes Mellitus, Type 2/genetics , Genetic Association Studies , Humans , Models, Genetic , Models, Statistical , Polymorphism, Single Nucleotide , Protein Interaction Mapping/statistics & numerical data
16.
Am J Med Genet B Neuropsychiatr Genet ; 153B(7): 1276-82, 2010 Oct 05.
Article in English | MEDLINE | ID: mdl-20872766

ABSTRACT

A recent genome-wide association study (GWAS) found significant association between the PALB2 SNP rs420259 and bipolar disorder (BD). The intracellular functions of the expressed proteins from the breast cancer risk genes PALB2 and BRCA2 are closely related. Therefore, we investigated the relation between genetic variants in PALB2 and BRCA2 and BD. Due to increasing evidence of genetic overlap between BD and schizophrenia (SCZ), we also investigated association with SCZ. In a Scandinavian case-control sample (n = 686/2,538) we found the BRCA2 SNP rs9567552 to be significantly associated with BD (Nominal P = 0.00043). Additionally, we replicated the association between PALB2 SNP rs420259 and BD (Nominal P = 0.025). We then combined our sample with another Nordic case-control sample (n = 435/11,491) from Iceland, and added results from the Wellcome Trust Case Control Consortium (WTCCC) (n = 1,868/2,938) and the STEP-UCL/ED-DUB-STEP2 study (n = 2,558/3,274) in a meta-analysis which revealed a P-value of 1.2 × 10(-5) for association between PALB2 SNP rs420259 and BD (n = 5,547/20,241). Neither the PALB2 SNP rs420259 nor the BRCA2 SNP rs9567552 were nominally significantly associated with the SCZ phenotype in our Scandinavian sample (n = 781/2,839). Our findings support PALB2 and BRCA2 as risk genes specifically for BD, and suggest that altered DNA repair related to neurogenesis may be involved in BD pathophysiology. © 2010 Wiley-Liss, Inc.


Subject(s)
BRCA2 Protein/genetics , Bipolar Disorder/genetics , Genetic Predisposition to Disease/genetics , Nuclear Proteins/genetics , Schizophrenia/genetics , Tumor Suppressor Proteins/genetics , Case-Control Studies , DNA Repair/genetics , Fanconi Anemia Complementation Group N Protein , Humans , Iceland , Neurogenesis/genetics , Polymorphism, Single Nucleotide , Scandinavian and Nordic Countries
17.
Psychiatr Genet ; 20(2): 59-64, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20023595

ABSTRACT

OBJECTIVES: Panic disorder (PD) is a common psychiatric disease occurring more frequently in women than men. Multiple common and/or rare variants in the genome contribute to the complex etiology of the disorder. The neuropeptide cholecystokinin (CCK) and its receptors (the CCK system) have been suggested to be involved in the pathogenesis of PD. METHODS: We examined the promoter, exon, and exon-intron boundaries of the genes encoding CCK and its receptors (CCKAR and CCKBR) for variations in 187 patients with PD and 277 screened control individuals. Up to 1342 additional healthy population controls were examined for some of the variations. One CCK gene intron variation was analyzed for alternative splicing using an exon-trapping assay. RESULTS: The promoter variant (-36C > T; rs1799923) and an intron 1 polymorphism (IVS1-7C > G; rs754635) in the CCK gene were found to protect against PD (P<0.05). The intron 1 variation did not seem to alter the splicing of the gene. None of the other variations found were associated with PD, but a 2-marker haplotype (rs1800855/rs1800857) in the CCKAR gene protected women against PD (P=0.004). In addition, we found two novel rare missense variations in the CCKBR gene (Lys329Asn and Pro446Leu) in two and one patient, respectively. CONCLUSION: The results suggest that the CCK system may play a role in the pathogenesis of PD, with susceptibility alleles both protecting and contributing to the disease. Both common and rare variants seem to be involved. The involvement of the CCK system may also contribute to the increased prevalence of PD in women.


Subject(s)
Cholecystokinin/genetics , Genetic Variation , Panic Disorder/genetics , Receptors, Cholecystokinin/genetics , Alternative Splicing , Exons , Female , Humans , Introns , Male , Promoter Regions, Genetic
18.
Scand J Clin Lab Invest ; 69(7): 801-8, 2009.
Article in English | MEDLINE | ID: mdl-19929724

ABSTRACT

Several single nucleotide polymorphisms (SNPs) have been identified in the beta(2)-adrenergic receptor gene (ADRB2). By the use of five SNPs (G46A, C79G, C491T, C523A, G1053C) for identification of ADRB2 haplotypes in 814 Danish Caucasians, we investigated whether ADRB2 haplotypes are associated with body mass index (BMI). The SNPs showed organization into 13 distinct haplotypes and 41 haplotype pairs. The study identified four common haplotypes: ACCCC (10.1 +/- 0.3 %), ACCCG (27.9 +/- 0.3 %), GCCAC (10.8 +/- 0.1 %) and GGCCG (41.0 +/- 0.2 %) (frequencies (SD), seen in 91 % of the population. In the total population (mean age +/- SD: 50 +/- 16 years), BMI was not related to haplotype pairs, individual SNPs or allelic haplotypes. However, in subjects < 50 years (N = 356, 36 +/- 8 years) BMI levels varied significantly between pairs of major haplotype groups (p = 0.014) but were not related to individual SNPs. In subjects < 37 years, the haplotype pair homozygote for the Gly16 and Glu27 amino acid variants (GGCCG/GGCCG) had a higher frequency of lean subjects (BMI < or = 25 kg/m(2)) compared with the GCCAC/GGCCG pair (73% versus 35%, odds ratio with 95% confidence interval: 4.95 (1.50-16.38). In conclusion, the haplotype analysis clearly revealed the prevalence of four major ADRB2 haplotypes in Caucasians. The results suggest that unique interactions in specific haplotype pairs rather than individual SNPs may affect BMI and that this effect of ADRB2 haplotypes is blunted by age-related factors.


Subject(s)
Body Mass Index , Haplotypes/genetics , Receptors, Adrenergic, beta-2/genetics , White People/genetics , Confidence Intervals , Denmark , Female , Humans , Linkage Disequilibrium/genetics , Male , Middle Aged , Odds Ratio , Polymorphism, Single Nucleotide/genetics
19.
J Neurol Sci ; 284(1-2): 90-5, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19423133

ABSTRACT

Hereditary spastic paraplegia (HSP) is a group of clinically and genetically heterogeneous neurodegenerative disorders characterized by progressive spasticity and weakness in the lower limbs. The most common forms of autosomal dominant HSP, SPG4 and SPG3, are caused by sequence variants in the SPAST and SPG3A genes, respectively. The pathogenic variants are scattered all over these genes and many variants are unique to a specific family. The phenotype in SPG4 patients can be modified by a variant in SPAST (p.Ser44Leu) and recently, a variant in HSPD1, the gene underlying SPG13, was reported as a second genetic modifier in SPG4 patients. In this study HSP patients were screened for variants in SPG3A, SPAST and HSPD1 in order to identify disease causing variations. SPAST was sequenced in all patients whereas subsets were sequenced in HSPD1 and in selected exons of SPG3A. SPG4 patients and their HSP relatives were genotyped for the modifying variant in HSPD1. We report six new sequence variants in SPAST including a fourth non synonymous sequence variant in exon 1 and two synonymous changes of which one has been found in a HSP patient previously, but never in controls. Of the novel variants in SPAST four were interpreted as disease causing. In addition one new disease causing sequence variant and one non pathogenic non synonymous variant were found in SPG3A. In HSPD1 we identified a sporadic patient homozygote for the potential modifying variation. The effect of the modifying HSPD1 variation was not supported by identification in one SPG4 family.


Subject(s)
Adenosine Triphosphatases/genetics , Amino Acid Substitution , Chaperonin 60/genetics , GTP Phosphohydrolases/genetics , Genetic Heterogeneity , Genetic Variation , Polymorphism, Single Nucleotide , Spastic Paraplegia, Hereditary/genetics , Adenosine Triphosphatases/chemistry , Adenosine Triphosphatases/physiology , Amino Acid Motifs , Cells, Cultured/chemistry , Chaperonin 60/chemistry , Chaperonin 60/physiology , DNA Mutational Analysis , Denmark/epidemiology , Female , Fibroblasts/chemistry , GTP Phosphohydrolases/chemistry , GTP Phosphohydrolases/physiology , GTP-Binding Proteins , Genotype , Humans , Male , Membrane Proteins , Mitochondrial Proteins , Pedigree , Phenotype , RNA Splice Sites/genetics , Sequence Analysis, DNA , Sequence Deletion , Spastic Paraplegia, Hereditary/epidemiology , Spastic Paraplegia, Hereditary/pathology , Spastin
20.
Psychiatr Genet ; 19(5): 269-72, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19478689

ABSTRACT

Single nucleotide polymorphisms (SNPs) in diacylglycerol kinase eta (DGKH) have recently been shown to be associated with bipolar disorder (BD). To replicate this finding, we carried out a gene-wide genotyping of 36 tagSNPs in DGKH and performed a population-based association study on two Scandinavian samples, with successful genotyping of 594 BD cases and 1421 healthy controls. We found no significant association after multiple-testing correction between any of these SNPs and BD in our sample. Thus, it is unlikely that these genetic variations confer susceptibility to BD in this large Scandinavian sample.


Subject(s)
Bipolar Disorder/genetics , Diacylglycerol Kinase/genetics , Genetic Predisposition to Disease , White People/genetics , Adult , Case-Control Studies , Female , Genetic Markers , Humans , Male , Middle Aged , Scandinavian and Nordic Countries
SELECTION OF CITATIONS
SEARCH DETAIL
...